Dosage of Tenax in details
Oral
Acute musculoskeletal disorders; Osteoarthritis; Rheumatoid arthritis
Adult: 20 mg as a single dose, taken at the same time each day. Treatment duration: Up to 7 days for acute musculoskeletal disorders and up to 14 days for severe cases.
Elderly: Use the lowest effective dose for the shortest possible duration.
Parenteral
Acute musculoskeletal disorders; Osteoarthritis; Rheumatoid arthritis
Adult: Initially, 20 mg IM/IV as a single dose given for 1-2 days, to be continued w/ the oral form, administered at the same time each day. Treatment duration: Up to 7 days for acute musculoskeletal disorders and up to 14 days for severe cases.
Elderly: Use the lowest effective dose for the shortest duration.
Reconstitution: Dissolve lyophilisate in 2 mL of sterile water for inj.
Tenax interactions
FELDENE is highly protein bound, and therefore, might be expected to displace other protein-bound drugs. Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs.
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels.
Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. It is recommended that plasma lithium levels be monitored when initiating, adjusting and discontinuing FELDENE.
References
- FDA/SPL Indexing Data. "Z1R9N0A399: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". https://www.fda.gov/ForIndustry/Data... (accessed September 17, 2018).
- MeSH. "Cyclooxygenase Inhibitors". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
- European Chemicals Agency - ECHA. "4-Hydroxy-2-methyl-N-pyridinyl-2H-thieno-[2,3-e]-1,2-thiazine-3-carboxamide 1,1-dioxide: The information provided here is aggregated from the "Notified classification and labelling" from ECHA's C&L Inventory. ". https://echa.europa.eu/information-o... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Tenax are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Tenax. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported frequency of use
No survey data has been collected yetConsumer reported doses
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
